BSX Q3 2025 Earnings Transcript

Boston Scientific delivered a strong Q3 beat, with organic revenue up 15.3% versus 12%-14% guidance and adjusted EPS of $0.75 versus $0.70-$0.72 expected. Management raised full-year organic growth guidance to 15.5% and adjusted EPS guidance to $3.02-$3.04, while operating margin expanded 80 bps to 28% despite an estimated $100 million tariff headwind. Growth was driven by EP, WATCHMAN, and U.S. performance, and the company reiterated a capital allocation focus on tuck-in M&A after closing Elutia assets and signing Nalu Medical.

Analysis

BSX’s beat is not just a top-line story; it is a proof point that the company is converting procedural mix into durable pricing power despite tariffs and a messy EMEA reset. The second-order implication is that investors may be underestimating how much of the margin trajectory is now self-funded by franchise mix rather than dependent on clean macro or one product cycle. That matters because it gives management more room to keep leaning into tuck-in M&A without sacrificing the 2026-2028 operating margin glidepath.

The real option value sits in WATCHMAN + EP + ASC migration. If concomitant keeps scaling and PFA moves further into persistent/redo cases, BSX gains a structural workflow advantage that is harder for competitors to replicate than a single-device share grab. The ASC reimbursement angle is important, but the near-term effect is more about backlog relief and account expansion than a step-function demand surge; that suggests the market may be front-running a 2026 catalyst that will actually be more visible in 2027-2028 volumes.

The main bear case is not demand, it is execution dispersion across the rest of the portfolio. Axonics remains a swing factor for Urology, China VBP keeps suppressing apparent growth in peripherals, and the EMEA ERP issue shows that operational complexity can still dent quarterly optics even in a strong franchise. Still, the guidance raise after already beating high expectations argues consensus was too conservative on the durability of BSX’s growth engine, while the tariff headwind looks increasingly like a manageable drag rather than a thesis-breaker.

Contrarianly, the market may be over-fixated on how much EP can decelerate and underappreciating the breadth of the next leg: neuromodulation adjacency expansion, AGENT indication expansion, and CRM platform refresh. Those are not same-quarter EPS drivers, but they are the pieces that can keep BSX compounding above medtech over a multi-year horizon. The key risk is that if WATCHMAN/EP adoption normalizes faster than expected, the stock can de-rate before the newer adjacencies are fully visible in reported numbers.

Key Decisions for Investors

• Go long BSX on a 3-6 month horizon into 2026 guidance season; risk/reward remains favorable because the market is likely still under-earning the durability of mix-driven margin expansion and has not fully priced the long-range FCF conversion.
• Pair trade: long BSX / short a basket of slower-growth large-cap medtech peers with weaker product cadence; BSX has the cleaner path to double-digit organic growth plus operating leverage, while peers face more muted mix and fewer near-term catalysts.
• Use pullbacks to add to BSX via call spreads expiring after Q1 2026; the asymmetry is that CHAMPION, PFA expansion, and WATCHMAN concomitant penetration could re-rate the multiple, while downside is buffered by recurring procedure demand and raised EPS guidance.
• Watch ELUT as a small-cap adjacency beneficiary only if integration data improves; otherwise treat the acquisition as strategically positive for BSX but not a standalone long, since value creation depends on BSX’s commercial platform execution over the next 12-18 months.
• Avoid chasing the move on the assumption that 2026 will repeat 2025’s growth rate; the better trade is to own BSX for the multi-year compounding story and size it against the risk that EP growth normalizes faster than the market expects.